Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will provide a company overview during fireside chats at the following upcoming investor conferences:
- Event: Credit Suisse 31st Annual Healthcare Conference
Location: Rancho Palos Verdes, CA
Date: Wednesday, November 9, 2022
Time: 12:50-1:20 PM PT / 3:50-4:20 PM ET
- Event: Stifel 2022 Healthcare Conference
Location: New York, NY
Date: Tuesday, November 15, 2022
Time: 3:00-3:30 PM ET
- Event: Jefferies London Healthcare Conference
Location: London, United Kingdom
Date: Thursday, November 17, 2022
Time: 8:35-9:05 AM GMT / 3:35-4:05 AM ET
Members of the Ventyx management team will also host investor meetings during the conferences.
Webcasts of the presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for thirty days.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three clinical-stage internally discovered programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
